FDA warns three US OTC drugmakers for lax component testing, missing validation programs
Regulatory NewsJoanne S. Eglovitch
Audit/inspectionNorth AmericaOTCPharmaceuticalsRegulatory NewsJoanne S. EglovitchAudit/inspectionNorth AmericaOTCPharmaceuticals